Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.

Journal of translational medicine - 21 Nov 2025

Song Ningning, Xi Xinquan, Zhang Kejian, Li Zeyu, Kuan Yang, Pei Chongzhe

Abstract excerpt

BACKGROUND: Women with autoimmune diseases (AIDs) experience chronic immune dysregulation and hormonal fluctuations, both of which may influence breast cancer risk. However, it remains unclear whether this risk is driven mainly by its treatment or the underlying disease, highlighting the need for integrating real-world data and genetic evidence. METHODS: The FDA Adverse Event Reporting System (FAERS) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Diseases
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to PARP1 gene

Share to TNF gene

Share to Genetic Predisposition to Disease

Share to Mendelian Randomization Analysis

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 41272700
DOI: 10.1186/s12967-025-07338-w
PMCID: PMC12639988

Genes

ADCY3
CALCRL
CENPO
FDPS
PARP1
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.PMID 41272700Read ↗

Mendelian randomization for autoimmune diseases: exploring causal links and drug targets in plasma proteomeSemantic proximity Read ↗

A genomic-led strategy to anticipate drug safety effectsSemantic proximity Read ↗

Elucidating the causal nexus between antibody-mediated immunity and autoimmune diseases: Insights from bidirectional mendelian randomization, gene expression profiling, and drug sensitivity analysis.Semantic proximity Read ↗

Adverse events induced by Burosumab treatment and prediction of drug target gene: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS) databaseSemantic proximity Read ↗

A genomic-led strategy to anticipate drug safety effects.Semantic proximity Read ↗

Mapping inherited genetic variation with opposite effects on autoimmune disease and cancer identifies candidate drug targets associated with the anti-tumor immune responseSemantic proximity Read ↗

Autoimmune diseases and risk of non-Hodgkin lymphoma: A Mendelian randomisation studySemantic proximity Read ↗

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidatesSemantic proximity Read ↗

The Oncology: Disease Modifying Anti-Rheumatic Drug Interface: A Cross-Specialty ReviewSemantic proximity Read ↗

Pharmacoepidemiology of autoimmune diseasesSemantic proximity Read ↗

No Evidence of Genotype‒Treatment Interactions between Endocrine Therapies and Adverse Drug Effects in Women with Breast Cancer: Findings from the UK BiobankSemantic proximity Read ↗

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.